Methods of detecting and treating colon disorders
The subject invention pertains to a method of detecting colon disorders including inflammatory bowel disease, such as Crohn's disease and ulcerative colitis, based on underexpression of Lipopolysaccharide Responsive Beige-like Anchor (LRBA). Advantageously, the invention may be used to test for inflammatory bowel disease using a blood sample from a subject before a more invasive test for colon disorders is employed. The invention also pertains to methods of treating a colon disorder in a subject in which the colon disorder is detected.
1. A method of detecting a colon disorder in a subject, comprising obtaining a sample comprising peripheral blood mononuclear cells (PBMCs) from the subject, and measuring a level or activity of Lipopolysaccharide Responsive Beige-like Anchor (LRBA) in the PBMCs, wherein a measured LRBA level or activity less than a normal control is indicative of the colon disorder, and wherein the colon disorder comprises inflammatory bowel disease or colon cancer.
2. The method of claim 1 , wherein the colon disorder is inflammatory bowel disease.
3. The method of claim 2 , wherein the inflammatory bowel disease is Crohn's disease or ulcerative colitis.
4. The method of claim 1 , wherein the colon disorder is colon cancer.
5. The method of claim 1 , further comprising carrying out one or more confirmatory tests for the colon disorder if the measured LRBA level is less than the normal control.
6. The method of claim 5 , wherein the one or more confirmatory tests is selected from the group consisting of a blood test, test for blood in a stool sample, test for a target microorganism in a stool sample, colonoscopy, sigmoidoscopy, X-ray with barium, computerized axial tomography, and capsule tomography, or a combination of two or more of the foregoing.
7. The method of claim 1 , wherein the sample is a blood sample.
8. The method of claim 1 , wherein said measuring comprises measuring the amount of LRBA messenger RNA in the PBMCs.
9. The method of claim 1 , wherein said measuring comprises measuring the amount of LRBA protein in the PBMCs.
10. The method of claim 1 , wherein said measuring comprises measuring the activity of LRBA in the PBMCs.
11. The method of claim 8 , wherein said measuring comprises contacting the sample with a detectably labeled nucleic acid that is complementary to a portion of LRBA messenger RNA.
12. The method of claim 9 , wherein said measuring comprises contacting the sample with a detectably labeled immunological reagent that binds to LRBA protein.
13. A method of detecting inflammatory bowel disease in a subject, comprising obtaining a sample comprising peripheral blood mononuclear cells (PBMCs) from the subject, and measuring Lipopolysaccharide Responsive Beige-like Anchor (LRBA) expression level in the PBMCs, wherein a measured LRBA expression level less than a normal control LRBA expression level is indicative of the inflammatory bowel disease.
14. The method of claim 13 , wherein said measuring comprises performing quantitative real-time polymerase chain reaction.
15. The method of claim 13 , wherein the inflammatory bowel disease comprises ulcerative colitis.
16. The method of claim 13 , wherein the inflammatory bowel disease comprises Crohn's disease.